CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

Bone Marrow Transplantation

Volumn 26, Issue 1, 2000, Pages 69-76

  Hale, G ^a,h   Jacobs, P ^b   Wood, L ^b   Fibbe, W E ^c   Barge, R ^d   Novitzky, N ^d   Du Toit, C ^d   Abrahams, L ^d   Thomas, V ^d   Bunjes, D ^e   Duncker, C ^e   Wiesneth, M ^e   Selleslag, D ^f   Hidajat, M ^f   Starobinski, M ^g   Bird, P ^a   Waldmann, H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Department of Haematology and Bone Marrow Transplantation Unit   (South Africa)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f General Hospital St Jan   (Belgium)

^g Hôpital Cantonal   (Switzerland)

^h Therapeutic Antibody Centre   (United Kingdom)

Author keywords

CAMPATH 1; Graftfailure; GVHD; HLA identical sibling; Peripheral blood progenitor cells; T cell depletion

Indexed keywords

ALEMTUZUMAB; CD34 ANTIGEN; CD52 ANTIGEN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RISK; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 0033949148     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702477     Document Type: Article

References (31)

1. Hale G. Campath-1 antigen (CD52). In: Delves PJ, Roitt I (eds). Encyclopedia of Immunology. Academic Press: London, 1998, pp 402-406.
2. Hale G, Bright S, Chumbley G et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873-882.
3. Hale G, Waldmann H for CAMPATH users. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with CAMPATH-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994; 13: 597-611.
4. Hale G, Waldmann H for CAMPATH users. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. Hematother 1994; 3: 15-31.
5. Bunjes D, Heit W, Arnold R et al. Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted HLA-identical bone marrow grafts. Transplantation 1987; 43: 501-505.
6. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell depleted HLA-identical marrow transplants for leukemia. Identification of host-derived anti-donor allocytotoxic T lymphocytes. Transplantation 1987; 43: 842-847.
7. Cobbold SP, Martin G, Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: the depletion of T-cell subsets in vitro and in vivo. Transplantation 1986; 42: 239-247.
8. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431-1439.
9. Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependant cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985; 134: 3056-3061.
10. Hale G, Zhang M-J, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581-4590.
11. Jacobs P, Wood L, Fullard L et al. T-cell depletion by exposure to CAMPATH-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1993; 13: 763-769.
12. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 322: 323-327.
13. Osterborg A, Fassas AS, Anagnostopoulos A et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukemia. Br J Haematol 1996; 93: 151-153.
14. Bowen AL, Zomas A, Emmett E et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997; 96: 617-619.
15. Hale G, Cobbold SP, Waldmann H et al. Isolation of low-frequency class-switch variants from rat hybrid myelomas. J Immunol Meth 1987; 103: 59-67.
16. Page MJ, Sydenham MA. High level expression of the humanized monoclonal antibody CAMPATH-1H in chinese hamster ovary cells. Bio/Technology 1991; 9: 64-68.
17. Chatenoud L, Ferran C, Legendre C et al. In vivo cell activation following OKT3 adminstration. Systematic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697-702.
18. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213-226.
19. Bensinger WI, Buckner CD. Allogeneic peripheral blood stem cell transplantation. In: Atkinson K (ed.). Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambride University Press: Cambridge, UK, 2000, pp 582-599.
20. Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Bone Marrow Transplant 1998; 22: 519-525.
21. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988; 18: 1507-1514.
22. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807-812.
23. Olweus J, Lund-Johansen F, Terstappen LWMM. Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells. Immunomethods 1996; 5: 179-186.
24. Williams RJ, Clarke E, Blair A et al. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in bone marrow and PBSC collections: comparison with CAMPATH-1M and CAMPATH-1G. Cytotherapy (in press).
25. Slaper-Cortenbach IC, Wijngaarden du Bois MJ, de Vries van Rossen A et al. The depletion of T cells from hematopoietic stem cell transplants. Rheumatol 1999; 38: 751-754.
26. Apperley JF, Mauro FR, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: importance of a graft-versus-leukemia effect. Br J Haematol 1988; 9: 239-245.
27. Novitzky N, Thomas V, Hale G, Waldmann, H. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia. Transplantation 1999; 67: 620-626.
28. Davison GM, Novitzky N, Kline A et al. Immune reconstitution following allogeneic bone marrow transplantation depleted of T-cells. Transplantation 2000; 69: 1341-1347.
29. Hale G, Waldmann H for CAMPATH users. Risks of developing EBV-related lymphoproliferative disorders following T cell depleted marrow transplants. Blood 1998; 91: 3079-3083.
30. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukamia in second complete remission. Br J Haematol 1996; 94: 574-578.
31. Koh MBC, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant 1999; 23: 1071-1079.